{"gene":"C3","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[],"current_model":"Parse failed"},"narrative":{"teleology":[],"mechanism_profile":null,"mechanistic_narrative":"Parse failed"},"prefetch_data":{"uniprot":{"accession":"P01024","full_name":"Complement C3","aliases":["C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1"],"length_aa":1663,"mass_kda":187.1,"function":"Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system Non-enzymatic component of C5 convertase (PubMed:28264884, PubMed:31507604, PubMed:3653927, PubMed:3897448). Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that marks the surface of antigens for removal (PubMed:28264884, PubMed:31507604, PubMed:3653927, PubMed:3897448, PubMed:833545, PubMed:8349625). Complement C3b binds covalently via its reactive thioester, to cell surface carbohydrates or immune aggregates (PubMed:6903192). Together with complement C4b, it then recruits the serine protease complement C2b to form the C5 convertase, which cleaves and activate C5, the next component of the complement pathways (PubMed:12878586, PubMed:18204047, PubMed:2387864). In the alternative complement pathway, recruits the serine protease CFB to form the C5 convertase that cleaves and activates C5 (PubMed:624565, PubMed:6554279) Mediator of local inflammatory process released following cleavage by C3 convertase (PubMed:6968751, PubMed:37169960, PubMed:37852260). Acts by binding to its receptor, C3AR1, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C3AR1 (PubMed:8702752, PubMed:37169960, PubMed:37852260). C3a anaphylatoxin stimulates the activation of immune cells such as mast cells and basophilic leukocytes to release inflammation agents, such as cytokines, chemokines and histamine, which promote inflammation development (PubMed:23383423). Also acts as potent chemoattractant for the migration of macrophages and neutrophils to the inflamed tissues, resulting in neutralization of the inflammatory triggers by multiple ways, such as phagocytosis and generation of reactive oxidants (PubMed:23383423, PubMed:342601, PubMed:5778786) Adipogenic hormone that stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance (PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750, PubMed:2909530, PubMed:8376604, PubMed:9059512). Appears to stimulate triglyceride synthesis via activation of the PLC, MAPK and AKT signaling pathways (PubMed:16333141). Acts by binding to its receptor, C5AR2, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C5AR2 (PubMed:11773063, PubMed:12540846, PubMed:19615750). In contrast to C3a anaphylatoxin peptide, does not show pro-inflammatory activity (PubMed:37852260) Acts as a chemoattractant for neutrophils in chronic inflammation","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01024/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/C3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"COPE","stoichiometry":0.2},{"gene":"DYNC1H1","stoichiometry":0.2},{"gene":"DYNLL2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/C3","total_profiled":1310},"omim":[{"mim_id":"621370","title":"X KELL BLOOD GROUP PRECURSOR-RELATED FAMILY, MEMBER 9; XKR9","url":"https://www.omim.org/entry/621370"},{"mim_id":"621306","title":"JUMONJI DOMAIN-CONTAINING PROTEIN 7; JMJD7","url":"https://www.omim.org/entry/621306"},{"mim_id":"620514","title":"IMMUNE DYSREGULATION, AUTOIMMUNITY, AND AUTOINFLAMMATION; IDAA","url":"https://www.omim.org/entry/620514"},{"mim_id":"620321","title":"C1q DEFICIENCY 2; C1QD2","url":"https://www.omim.org/entry/620321"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":5062.4}],"url":"https://www.proteinatlas.org/search/C3"},"hgnc":{"alias_symbol":["CPAMD1","ARMD9","C3a","C3b"],"prev_symbol":[]},"alphafold":{"accession":"P01024","domains":[{"cath_id":"2.60.40.1930","chopping":"26-124","consensus_level":"high","plddt":85.1921,"start":26,"end":124},{"cath_id":"2.60.40.1930","chopping":"130-217","consensus_level":"high","plddt":82.5127,"start":130,"end":217},{"cath_id":"2.60.40.1940","chopping":"233-350","consensus_level":"high","plddt":78.9626,"start":233,"end":350},{"cath_id":"2.60.40.10","chopping":"352-448","consensus_level":"medium","plddt":86.8403,"start":352,"end":448},{"cath_id":"2.60.40.1930","chopping":"455-557","consensus_level":"medium","plddt":87.3104,"start":455,"end":557},{"cath_id":"2.20.130.20","chopping":"564-620_767-826","consensus_level":"medium","plddt":85.8909,"start":564,"end":826},{"cath_id":"1.20.91.20","chopping":"679-733","consensus_level":"medium","plddt":81.9093,"start":679,"end":733},{"cath_id":"2.60.40.10","chopping":"830-871_880-933","consensus_level":"high","plddt":75.5402,"start":830,"end":933},{"cath_id":"2.60.120.1540","chopping":"942-986_1290-1351","consensus_level":"medium","plddt":83.3435,"start":942,"end":1351},{"cath_id":"2.60.40.690","chopping":"1353-1494","consensus_level":"high","plddt":73.4821,"start":1353,"end":1494},{"cath_id":"2.40.50.120","chopping":"1504-1663","consensus_level":"medium","plddt":78.0555,"start":1504,"end":1663}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01024","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01024-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01024-F1-predicted_aligned_error_v6.png","plddt_mean":79.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=C3","jax_strain_url":"https://www.jax.org/strain/search?query=C3"},"sequence":{"accession":"P01024","fasta_url":"https://rest.uniprot.org/uniprotkb/P01024.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01024/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01024"}},"corpus_meta":[{"pmid":"16452172","id":"PMC_16452172","title":"Drusen complement components C3a and C5a promote choroidal neovascularization.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16452172","citation_count":534,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6209300","id":"PMC_6209300","title":"Human neutrophils increase expression of C3bi as well as C3b receptors upon activation.","date":"1984","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/6209300","citation_count":392,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12975457","id":"PMC_12975457","title":"The proinflammatory mediators C3a and C5a are essential for liver regeneration.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12975457","citation_count":335,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17051160","id":"PMC_17051160","title":"Structure of C3b reveals conformational changes that underlie complement activity.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17051160","citation_count":295,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10984054","id":"PMC_10984054","title":"A role for the C3a anaphylatoxin receptor in the effector phase of asthma.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10984054","citation_count":278,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6225825","id":"PMC_6225825","title":"Fibronectin and serum amyloid P component stimulate C3b- and C3bi-mediated phagocytosis in cultured human monocytes.","date":"1983","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6225825","citation_count":259,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2951479","id":"PMC_2951479","title":"Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins.","date":"1987","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2951479","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22118769","id":"PMC_22118769","title":"Complement fragment C3a controls mutual cell attraction during collective cell migration.","date":"2011","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22118769","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17051150","id":"PMC_17051150","title":"Structure of C3b in complex with CRIg gives insights into regulation of complement activation.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17051150","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17322907","id":"PMC_17322907","title":"C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17322907","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6604123","id":"PMC_6604123","title":"Human platelet activation by C3a and C3a des-arg.","date":"1983","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6604123","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11939578","id":"PMC_11939578","title":"Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.","date":"2002","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11939578","citation_count":177,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12165538","id":"PMC_12165538","title":"Complement c3a and c5a induce different signal transduction cascades in endothelial cells.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12165538","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7284336","id":"PMC_7284336","title":"Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties.","date":"1981","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7284336","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7513741","id":"PMC_7513741","title":"Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.","date":"1994","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7513741","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18684951","id":"PMC_18684951","title":"A new map of glycosaminoglycan and C3b binding sites on factor H.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18684951","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1056006","id":"PMC_1056006","title":"Third component of complement (C3): structural properties in relation to functions.","date":"1975","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1056006","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6339618","id":"PMC_6339618","title":"Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase.","date":"1983","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6339618","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12081998","id":"PMC_12081998","title":"Influence of C3 deficiency on atherosclerosis.","date":"2002","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12081998","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6223944","id":"PMC_6223944","title":"Genetic regulation of a structural polymorphism of human C3b receptor.","date":"1983","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/6223944","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1238393","id":"PMC_1238393","title":"Human anaphylatoxin (C3a) from the third component of complement. Primary structure.","date":"1975","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1238393","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10340761","id":"PMC_10340761","title":"Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells.","date":"1999","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10340761","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7252422","id":"PMC_7252422","title":"Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.","date":"1981","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7252422","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22246034","id":"PMC_22246034","title":"A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22246034","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12393727","id":"PMC_12393727","title":"An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393727","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7276561","id":"PMC_7276561","title":"Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer.","date":"1981","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7276561","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25289982","id":"PMC_25289982","title":"Human C3b- and C4b-regulatory proteins: a new multi-gene family.","date":"1985","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/25289982","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"332718","id":"PMC_332718","title":"Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans.","date":"1977","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/332718","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27956400","id":"PMC_27956400","title":"Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia.","date":"2016","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27956400","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"803505","id":"PMC_803505","title":"Purification and partial characterization of human and porcine C3a anaphylatoxin.","date":"1975","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/803505","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6451220","id":"PMC_6451220","title":"Purification of the human complement control protein C3b inactivator.","date":"1980","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/6451220","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29233958","id":"PMC_29233958","title":"Complement C3a signaling facilitates skeletal muscle regeneration by regulating monocyte function and trafficking.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29233958","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27746894","id":"PMC_27746894","title":"Characterization of a functional C3A liver spheroid model.","date":"2016","source":"Toxicology research","url":"https://pubmed.ncbi.nlm.nih.gov/27746894","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2409200","id":"PMC_2409200","title":"Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.","date":"1985","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2409200","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11086104","id":"PMC_11086104","title":"Activated human T lymphocytes express a functional C3a receptor.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11086104","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1500721","id":"PMC_1500721","title":"Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1500721","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"448074","id":"PMC_448074","title":"Action of the C3b-inactivator on the cell-bound C3b.","date":"1979","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/448074","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25447133","id":"PMC_25447133","title":"Histopathology of MPGN and C3 glomerulopathies.","date":"2014","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/25447133","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1373170","id":"PMC_1373170","title":"A mechanism of action for anaphylatoxin C3a stimulation of mast cells.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1373170","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9886419","id":"PMC_9886419","title":"Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg).","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9886419","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2952524","id":"PMC_2952524","title":"The superfamily of C3b/C4b-binding proteins.","date":"1987","source":"Federation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/2952524","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23689905","id":"PMC_23689905","title":"Eculizumab and recurrent C3 glomerulonephritis.","date":"2013","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/23689905","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35777783","id":"PMC_35777783","title":"Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy.","date":"2022","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/35777783","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3160931","id":"PMC_3160931","title":"Mouse monoclonal antibodies to the human C3b receptor.","date":"1985","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3160931","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21337338","id":"PMC_21337338","title":"Improvement of HepG2/C3a cell functions in a microfluidic biochip.","date":"2011","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/21337338","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16154494","id":"PMC_16154494","title":"The C3a receptor antagonist SB 290157 has agonist activity.","date":"2005","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16154494","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20031321","id":"PMC_20031321","title":"Nociceptive sensitization by complement C5a and C3a in mouse.","date":"2009","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/20031321","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15286806","id":"PMC_15286806","title":"The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15286806","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26867858","id":"PMC_26867858","title":"Towards engineering carboxysomes into C3 plants.","date":"2016","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26867858","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8609428","id":"PMC_8609428","title":"Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8609428","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6227098","id":"PMC_6227098","title":"The human C3b receptor.","date":"1983","source":"Springer seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/6227098","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20186746","id":"PMC_20186746","title":"Complement fragments C3a and C5a: the salt and pepper of the immune response.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20186746","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9607842","id":"PMC_9607842","title":"Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells.","date":"1998","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/9607842","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27056062","id":"PMC_27056062","title":"C3 Glomerulopathy.","date":"2016","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/27056062","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3643213","id":"PMC_3643213","title":"Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.","date":"1987","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3643213","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24327134","id":"PMC_24327134","title":"C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy.","date":"2013","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24327134","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17051152","id":"PMC_17051152","title":"The structure of complement C3b provides insights into complement activation and regulation.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17051152","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6553050","id":"PMC_6553050","title":"C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.","date":"1983","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6553050","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9832147","id":"PMC_9832147","title":"Expression of a functional anaphylatoxin C3a receptor by astrocytes.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9832147","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32973774","id":"PMC_32973774","title":"The Complement C3a and C3a Receptor Pathway in Kidney Diseases.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32973774","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6222733","id":"PMC_6222733","title":"Enzymic assay of C3b receptor on intact cells and solubilized cells.","date":"1983","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/6222733","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1826092","id":"PMC_1826092","title":"Internalization pathway of C3b receptors in human neutrophils and its transmodulation by chemoattractant receptors stimulation.","date":"1991","source":"Cell regulation","url":"https://pubmed.ncbi.nlm.nih.gov/1826092","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15056381","id":"PMC_15056381","title":"Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons.","date":"2004","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15056381","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24723409","id":"PMC_24723409","title":"Photosynthesis of C3, C3-C4, and C4 grasses at glacial CO2.","date":"2014","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/24723409","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25465103","id":"PMC_25465103","title":"Activation of C3a receptor is required in cigarette smoke-mediated emphysema.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25465103","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19684087","id":"PMC_19684087","title":"Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19684087","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21357400","id":"PMC_21357400","title":"Expression of complement component 3 (C3) from an adenovirus leads to pathology in the murine retina.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21357400","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9603462","id":"PMC_9603462","title":"Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9603462","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27507892","id":"PMC_27507892","title":"Characterization of C3 in C3 glomerulopathy.","date":"2017","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/27507892","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17169328","id":"PMC_17169328","title":"Antifungal activity of C3a and C3a-derived peptides against Candida.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17169328","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21677637","id":"PMC_21677637","title":"Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21677637","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12871936","id":"PMC_12871936","title":"Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12871936","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25972241","id":"PMC_25972241","title":"Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25972241","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16982879","id":"PMC_16982879","title":"Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16982879","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16148115","id":"PMC_16148115","title":"Complement C3a enhances CXCL12 (SDF-1)-mediated chemotaxis of bone marrow hematopoietic cells independently of C3a receptor.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16148115","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2944517","id":"PMC_2944517","title":"Hematologic correlates and the role of erythrocyte CR1 (C3b receptor) in the development of AIDS.","date":"1986","source":"AIDS research","url":"https://pubmed.ncbi.nlm.nih.gov/2944517","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27038285","id":"PMC_27038285","title":"Glycine decarboxylase in C3, C4 and C3-C4 intermediate species.","date":"2016","source":"Current opinion in plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/27038285","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6445926","id":"PMC_6445926","title":"Control of serum C3 levels by beta 1H and C3b inactivator.","date":"1980","source":"The Journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6445926","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17984207","id":"PMC_17984207","title":"Defining targets for complement components C4b and C3b on the pathogenic neisseriae.","date":"2007","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17984207","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8406589","id":"PMC_8406589","title":"Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages.","date":"1993","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8406589","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8946437","id":"PMC_8946437","title":"Regulation of alternative pathway activation and C3a production by adipose cells.","date":"1996","source":"Obesity research","url":"https://pubmed.ncbi.nlm.nih.gov/8946437","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33493474","id":"PMC_33493474","title":"Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression.","date":"2021","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/33493474","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30944246","id":"PMC_30944246","title":"C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30944246","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33936031","id":"PMC_33936031","title":"The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33936031","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17687277","id":"PMC_17687277","title":"Crystallography: crystallographic evidence for deviating C3b structure.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17687277","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30825266","id":"PMC_30825266","title":"Complement C3a promotes proliferation, migration and stemness in cutaneous squamous cell carcinoma.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30825266","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24967582","id":"PMC_24967582","title":"Vimentin mediates uptake of C3 exoenzyme.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24967582","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11814627","id":"PMC_11814627","title":"Albutensin A and complement C3a decrease food intake in mice.","date":"2002","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/11814627","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20813409","id":"PMC_20813409","title":"CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.","date":"2010","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20813409","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3295051","id":"PMC_3295051","title":"Phylogeny of C4b-C3b cleaving activity: similar fragmentation patterns of human C4b and C3b produced by lower animals.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3295051","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32762445","id":"PMC_32762445","title":"Protective Role of C3aR (C3a Anaphylatoxin Receptor) Against Atherosclerosis in Atherosclerosis-Prone Mice.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32762445","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20527893","id":"PMC_20527893","title":"Selective hexapeptide agonists and antagonists for human complement C3a receptor.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20527893","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26116506","id":"PMC_26116506","title":"Properdin Contributes to Allergic Airway Inflammation through Local C3a Generation.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26116506","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2978518","id":"PMC_2978518","title":"C3 receptors on macrophages.","date":"1988","source":"Journal of cell science. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/2978518","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35598724","id":"PMC_35598724","title":"Involvement of complement peptides C3a and C5a in osteoarthritis pathology.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35598724","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31798904","id":"PMC_31798904","title":"Deficiency of C3a receptor attenuates the development of diabetic nephropathy.","date":"2019","source":"BMJ open diabetes research & care","url":"https://pubmed.ncbi.nlm.nih.gov/31798904","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27878657","id":"PMC_27878657","title":"C3 glomerulopathy and current dilemmas.","date":"2016","source":"Clinical and experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27878657","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24068526","id":"PMC_24068526","title":"C3 nephritic factor associated with C3 glomerulopathy in children.","date":"2013","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/24068526","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7121468","id":"PMC_7121468","title":"Biotinylation of human C3.","date":"1982","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7121468","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23689580","id":"PMC_23689580","title":"C3 glomerulopathy.","date":"2013","source":"Contributions to nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/23689580","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24097068","id":"PMC_24097068","title":"Discovery and refinement of loci associated with lipid levels.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24097068","citation_count":2409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12754519","id":"PMC_12754519","title":"Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12754519","citation_count":1176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15454921","id":"PMC_15454921","title":"The complement system in regulation of adaptive immunity.","date":"2004","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15454921","citation_count":736,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3052276","id":"PMC_3052276","title":"Molecular organization and function of the complement system.","date":"1988","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3052276","citation_count":716,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17634448","id":"PMC_17634448","title":"Complement C3 variant and the risk of age-related macular degeneration.","date":"2007","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17634448","citation_count":690,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23455636","id":"PMC_23455636","title":"Seven new loci associated with age-related macular degeneration.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23455636","citation_count":649,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"342601","id":"PMC_342601","title":"Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.","date":"1978","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/342601","citation_count":640,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22074402","id":"PMC_22074402","title":"Antimicrobial peptides: key components of the innate immune system.","date":"2011","source":"Critical reviews in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22074402","citation_count":565,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"833545","id":"PMC_833545","title":"The role of membrane receptors for C3b and C3d in phagocytosis.","date":"1977","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/833545","citation_count":535,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"5778786","id":"PMC_5778786","title":"Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.","date":"1969","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/5778786","citation_count":475,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16530040","id":"PMC_16530040","title":"CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16530040","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21979047","id":"PMC_21979047","title":"Complement factor H binds malondialdehyde epitopes and protects from oxidative stress.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21979047","citation_count":445,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15199963","id":"PMC_15199963","title":"The lectin-complement pathway--its role in innate immunity and evolution.","date":"2004","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15199963","citation_count":443,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16177781","id":"PMC_16177781","title":"Structures of complement component C3 provide insights into the function and evolution of immunity.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16177781","citation_count":439,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22456601","id":"PMC_22456601","title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.","date":"2012","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/22456601","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385819","id":"PMC_20385819","title":"Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385819","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2579379","id":"PMC_2579379","title":"Human complement component C3: cDNA coding sequence and derived primary structure.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2579379","citation_count":411,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19290921","id":"PMC_19290921","title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290921","citation_count":400,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12679444","id":"PMC_12679444","title":"Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12679444","citation_count":388,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6912277","id":"PMC_6912277","title":"Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.","date":"1981","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6912277","citation_count":381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385826","id":"PMC_20385826","title":"Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385826","citation_count":376,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49500,"output_tokens":9214,"usd":0.143355},"stage2":{"model":"claude-opus-4-6","input_tokens":13119,"output_tokens":3907,"usd":0.244905},"total_usd":0.601014,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61836,"output_tokens":16000,"usd":0.212754},"round2_rules_fired":"R3"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1975,\n      \"finding\": \"C3 is cleaved by C3 convertase at the alpha-chain, releasing the 9,000 Da anaphylatoxin fragment C3a from the N-terminal portion, and exposing a transient binding region in C3b that mediates attachment to biological membranes via the C3d portion. Subsequent fragments C3c and C3d arise from further enzymatic cleavage of the alpha-chain.\",\n      \"method\": \"Biochemical fractionation, SDS-PAGE, functional hemolytic assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational biochemical reconstitution with structural and functional validation, replicated across multiple labs\",\n      \"pmids\": [\"1056006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"Human C3a anaphylatoxin is a 77-amino-acid, single polypeptide chain with a C-terminal arginine essential for smooth muscle contraction and mast cell histamine release; the six half-cystines form three disulfide linkages. The COOH-terminal cationic region is required for receptor interaction.\",\n      \"method\": \"Protein purification, amino acid sequencing, bioassays (guinea pig ileum contraction, histamine release)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary structure determination with functional validation of active residues\",\n      \"pmids\": [\"1238393\", \"803505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1980,\n      \"finding\": \"C3b inactivator (factor I) cleaves C3b in conjunction with its cofactor beta1H (factor H), requiring beta1H for both soluble and cell-bound C3b cleavage. The alpha'-chain of C3b is cleaved into 67,000 and 43,000 Da fragments. Native C3 is not a substrate for C3bINA + beta1H.\",\n      \"method\": \"In vitro protease assay, SDS-PAGE of cleavage products, purification of C3bINA\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with defined substrates and enzyme characterization\",\n      \"pmids\": [\"6451220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1979,\n      \"finding\": \"C3bINA and beta1H act on cell-bound C3b to cleave the alpha-polypeptide into 60 kDa (C3b-alpha-60, which retains the covalent bond to the cell surface) and 40 kDa fragments, generating C3b' (iC3b). This conversion abolishes alternative pathway C3 convertase activity and immune adherence, but does not affect anti-C3c or anti-C3d reactivity.\",\n      \"method\": \"Functional hemolytic assays, SDS-PAGE of cell-bound C3b fragments, immune adherence assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution on cell surfaces with well-defined functional readouts\",\n      \"pmids\": [\"448074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Nucleophilic modification of C3 (methylamine or freeze-thaw) produces C3b-like conformational changes including exposure of a free sulfhydryl group and increased surface hydrophobicity, recapitulating C3b functional properties (factor B binding, susceptibility to C3b inactivator) without peptide bond cleavage. Conformational rearrangement follows the chemical modification and is kinetically separable from loss of hemolytic activity.\",\n      \"method\": \"Near-UV circular dichroism, ANS fluorescence, functional assays (factor B binding, C3b inactivator cleavage)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biophysical and functional methods in a single rigorous study\",\n      \"pmids\": [\"7284336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Mast cell tryptase cleaves only the alpha-chain of C3 in vitro, generating a 9 kDa fragment (C3a) identified by co-migration with authentic C3a, radioimmunoassay, and guinea pig ileum bioassay. Heparin (co-released from mast cells) accelerates C3a catabolism by tryptase, providing a feedback inactivation mechanism.\",\n      \"method\": \"SDS-PAGE, radioimmunoassay, bioassay (guinea pig ileum contraction), enzyme activity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with multiple orthogonal identification methods for C3a product\",\n      \"pmids\": [\"6339618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C3a (and C3a des-Arg) directly activates human platelets, inducing aggregation and serotonin release at concentrations as low as 10^-12 M; removal of the C-terminal arginine abolishes anaphylatoxin activity but not platelet-stimulating activity. Ultrastructural analysis demonstrated C3a binding to the platelet membrane, suggesting a specific C3a receptor on platelets.\",\n      \"method\": \"Platelet aggregation assay, serotonin release assay, electron microscopy, synergism analysis with ADP\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with defined ligand and mutagenesis (des-Arg form) plus ultrastructural localization\",\n      \"pmids\": [\"6604123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"The C3b receptor (CR1) on human PMN mediates adsorptive endocytosis requiring bivalent (not monovalent) ligand crosslinking and is internalized via a mechanism that renders the receptor inaccessible to external antibody. C3b-opsonized particles (C3b-OR) remain on the cell surface unless cross-linked with anti-C3 antibody.\",\n      \"method\": \"Quantitative immunofluorescence, radiolabeled antibody internalization assay, pronase accessibility assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods demonstrating receptor crosslinking requirement for endocytosis\",\n      \"pmids\": [\"7252422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C3b receptor (CR1) on erythrocytes and B-lymphocytes acts as a cofactor for factor I (C3b/C4b inactivator) to cleave C3b. Lymphocytes contain a large internal pool (>80% of total cofactor activity) not present at the cell surface, distinguishing them from erythrocytes where essentially all receptors are surface-exposed.\",\n      \"method\": \"Enzymic cofactor assay on intact and permeabilized cells, comparison of CR1 activity on erythrocytes vs. lymphocytes\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic assay with subcellular fractionation\",\n      \"pmids\": [\"6222733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C3a stimulates histamine release from human skin mast cells in a non-cytotoxic, calcium-independent manner; removal of the C-terminal arginine abolishes activity. C3a and C5a activate mast cells through a mechanism distinct from substance P.\",\n      \"method\": \"Histamine release assay, pharmacological inhibitors, calcium-free conditions\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with pharmacological dissection and modified ligand controls\",\n      \"pmids\": [\"7513741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C3b receptor on human erythrocytes binds dimeric C3b with >25-fold higher affinity than monomeric C3b (Kd ~9.53 nM for dimer). Binding is specific, saturable, reversible, and does not exhibit cooperativity. Receptor density varies among cell types: ~360/erythrocyte, ~20,000/PMN, ~30,000/monocyte, ~21,000/B cell.\",\n      \"method\": \"125I-labeled C3b binding kinetics and Scatchard analysis, multiple human cell types\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative ligand binding study replicated across multiple cell types\",\n      \"pmids\": [\"7276561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Both CR3 (C3bi receptor) and CR1 (C3b receptor) expression on human PMN increases rapidly upon activation (fMLP or Raji cell supernatant), involving translocation from an intracellular storage pool (not de novo synthesis), as shown by resistance to protein synthesis inhibitors and rapid kinetics (complete within minutes).\",\n      \"method\": \"Monoclonal antibodies, flow cytometry, protein synthesis inhibitor (puromycin, cycloheximide) experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional upregulation with mechanistic demonstration of intracellular pool translocation\",\n      \"pmids\": [\"6209300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Fibronectin (substrate-bound, not soluble) and serum amyloid P component activate C3b- and C3bi-mediated phagocytosis in cultured human monocytes but not granulocytes, in a developmentally regulated manner. Stimulation of the basal surface of monocytes activates C3 receptors on the apical surface (remote activation).\",\n      \"method\": \"Phagocytosis assay, substrate vs. soluble FN comparison, monocyte maturation experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional experiments with mechanistic dissection\",\n      \"pmids\": [\"6225825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"C3b and iC3b deposit on both classical and alternative pathway activators; C3b is rapidly converted to iC3b (within 15-30 min), and iC3b is the predominant form encountered by phagocytes on most activators. On bacteria, ~75-85% of bound C3 remains as C3b even after 2 hours, unlike erythrocytes.\",\n      \"method\": \"Monoclonal antibody-based quantitative immunoassay, kinetic analysis, SDS-PAGE autoradiography of 125I-C3 fragments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative, kinetic study with multiple activators and orthogonal methods\",\n      \"pmids\": [\"2409200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Human CR1 consists of at least four tandem long homologous repeats (LHRs) of ~450 amino acids, each comprising 7 short consensus repeats (SCRs) of ~60-70 amino acids similar to other C3/C4-binding proteins. The receptor has a single membrane-spanning domain and a 43-residue cytoplasmic tail with a PKC phosphorylation site.\",\n      \"method\": \"cDNA cloning and sequencing, tryptic peptide analysis, amino acid sequencing\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary structure determination with domain identification and functional mapping\",\n      \"pmids\": [\"2951479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The alternative complement pathway C3 convertase (C3b,Bb) is an active complex with a sedimentation coefficient of 10.7S containing one metal ion (Mg2+ or Ni2+) per complex, located in the Bb subunit. Formation involves two points of contact between factor B and C3b: one in the Ba domain and one in the Bb domain.\",\n      \"method\": \"Sucrose density gradient ultracentrifugation, 63Ni radioisotope tracing, enzymatic activity assay, crosslinking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with radioisotope tracing and enzyme activity\",\n      \"pmids\": [\"6553050\", \"3643213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Human PMN synthesize and secrete functional C3 (with intact thioester bond) in response to LPS or TNF-alpha stimulation, as shown by 35S-methionine labeling, immunoprecipitation, and 14C-methylamine incorporation. C3 secretion was ~4 ng/ml per 10^7 cells after LPS stimulation.\",\n      \"method\": \"Northern blot, ELISA, immunoprecipitation with SDS-PAGE, 35S-methionine labeling, 14C-methylamine incorporation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including metabolic labeling and thioester assay\",\n      \"pmids\": [\"1500721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"C3a stimulates mast cell histamine release via G protein activation (pertussis toxin-sensitive), inositol polyphosphate generation, and direct stimulation of Gi-type G proteins (GTPase activity), suggesting direct G protein interaction rather than a conventional receptor-mediated mechanism. C3a C-terminal analogues recapitulate this activity.\",\n      \"method\": \"Histamine release assay, inositol phosphate assay, GTPase activity assay with purified G proteins, pertussis toxin inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional pharmacological dissection with purified G proteins, but one lab\",\n      \"pmids\": [\"1373170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Extrahepatic C3 from non-myeloid sources accounts for 3.1-5.7% of total circulating C3 (measured in liver transplant recipients with C3 allotype mismatch). Monocytes (bone marrow-derived) contribute 0.1-2.6% during inflammation but negligible amounts at rest.\",\n      \"method\": \"C3 allotype-specific ELISA, immunoblotting in bone marrow and liver transplant recipients with allotype mismatch\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural allotype mismatch experiment in transplant patients provides clean in vivo source tracing\",\n      \"pmids\": [\"8609428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Genetic deletion of the C3a receptor (C3aR) in mice protects against allergen-induced changes in lung physiology (asthma model), and human asthmatics generate significant C3a following intra-pulmonary allergen challenge. C3a/C3aR signaling mediates airway hyperresponsiveness in vivo.\",\n      \"method\": \"C3aR knockout mice, lung physiology measurements, clinical measurement of C3a in BAL from human asthmatics\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined physiological phenotype and human clinical data\",\n      \"pmids\": [\"10984054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Carboxypeptidase R (TAFI/proCPR) cleaves terminal arginine from C3a (and C5a) upon activation by thrombin/thrombomodulin or plasmin, more efficiently than carboxypeptidase N, providing a major inactivation mechanism for C3a in the inflammatory state.\",\n      \"method\": \"In vitro enzymatic assay with C3a octapeptide substrate, comparison of enzyme kinetics between CPR and CPN\",\n      \"journal\": \"Microbiology and immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay, single lab\",\n      \"pmids\": [\"11939578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C3a receptor activation in endothelial cells causes transient actin stress fiber formation via Rho activation coupled to G-alpha12/13 (pertussis toxin-insensitive), whereas C5aR causes delayed cytoskeletal retraction, increased paracellular permeability, and EGFR transactivation. These signaling cascades differ from those in leukocytes.\",\n      \"method\": \"Pharmacological inhibitors, pertussis toxin, immune precipitation of EGFR phosphorylation, permeability assay, cell migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods identifying distinct G-protein coupling and downstream pathways\",\n      \"pmids\": [\"12165538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C3a and C5a are essential for liver regeneration: C3- or C5-deficient mice show high mortality and impaired regeneration after partial hepatectomy. C3a and C5a mediate their effects by activating NF-kappaB/STAT-3 and inducing IL-6/TNF-alpha, with dual C3/C5 deficiency phenotype reversed by combined C3a and C5a reconstitution.\",\n      \"method\": \"C3/C5 knockout mice, partial hepatectomy, reconstitution with recombinant C3a/C5a, NF-kappaB/STAT-3 activation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with reconstitution experiment and defined signaling pathway, rigorous epistasis\",\n      \"pmids\": [\"12975457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tyrosine 174 in the second extracellular loop of C3aR is sulfated, and this sulfotyrosine is the critical docking site for native C3a binding; Y174F mutation completely blocks C3a binding but not signaling by synthetic C3a agonist peptides. Other sulfated tyrosines (184, 188, 317, 318) are not required for ligand binding.\",\n      \"method\": \"Site-directed mutagenesis, radioligand binding assay, calcium mobilization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis + functional assay demonstrating specific sulfotyrosine requirement\",\n      \"pmids\": [\"12871936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of C3b at 4 Å resolution reveals dramatic conformational rearrangements of 12 domains upon proteolytic activation: the thioester-containing domain moves >85 Å, fully exposing the thioester for covalent attachment to surfaces. These changes expose cryptic binding sites for factor B, factor H, and other complement regulators.\",\n      \"method\": \"X-ray crystallography (4 Å resolution)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional implications validated by known biology\",\n      \"pmids\": [\"17051160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of C3b in complex with CRIg demonstrates that CRIg binds specifically to C3b (and iC3b) and functions as an inhibitor of alternative pathway C3 convertase. CRIg mutant studies show it blocks convertase activity while mediating phagocytosis. The structure confirms the >80 Å movement of the thioester domain upon C3 activation.\",\n      \"method\": \"X-ray crystallography, CRIg mutagenesis, convertase inhibition assay, phagocytosis assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis and functional validation\",\n      \"pmids\": [\"17051150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3a and C5a bioactive fragments are present in drusen of AMD patients and induce VEGF expression in vitro and in vivo. Genetic ablation of C3a or C5a receptors reduces VEGF expression, leukocyte recruitment, and choroidal neovascularization after laser injury. C3a and C5a are generated early in laser-induced CNV.\",\n      \"method\": \"Knockout mice, laser-induced CNV model, VEGF assays, antibody neutralization, pharmacological receptor blockade\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (genetic, antibody, pharmacological) with defined mechanistic outcome\",\n      \"pmids\": [\"16452172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C5L2 (GPR77) functions as a positive modulator of both C5a- and C3a-anaphylatoxin-induced responses. C5L2 deficiency reduces inflammatory cell infiltration, and C5L2-deficient mice phenocopy C3a/C3aR deficient mice in hypersensitivity to LPS, reduced airway hyperresponsiveness, and delayed hematopoietic regeneration.\",\n      \"method\": \"Gene targeting (knockout mice), in vitro signaling assays in neutrophils/macrophages/fibroblasts, in vivo inflammatory models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple in vitro and in vivo phenotypic readouts\",\n      \"pmids\": [\"17322907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Factor H contains distinct C3b-binding sites in CCPs 1-4 and 19-20 (Kd ~10-14 µM and ~3.5-4.5 µM respectively) and glycosaminoglycan-binding sites in CCPs 7-8 and 19-20. Previously reported C3b and heparin binding to CCPs 8-9, 12-13, and 9-15 were not confirmed; some prior results were due to non-native residues.\",\n      \"method\": \"Recombinant CCP module expression, heparin-affinity chromatography, gel-mobility shift assay, surface plasmon resonance\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding assays with defined recombinant modules and quantitative affinity measurements\",\n      \"pmids\": [\"18684951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Neural crest cells are coattracted via C3a and its receptor C3aR during collective cell migration in vertebrate development. Loss of C3a/C3aR-mediated coattraction disrupts cohesive cluster movement and coordination of neural crest cells.\",\n      \"method\": \"In vivo loss-of-function (C3aR knockdown), live imaging of neural crest migration, cell cluster cohesion assay\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with live imaging and defined cellular phenotype\",\n      \"pmids\": [\"22118769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The C3 R139W mutation (prevalent in aHUS patients) causes a gain-of-function hyperactive C3 convertase by increasing C3 affinity for factor B and reducing binding to membrane cofactor protein (MCP/CD46), while normal factor H regulation is retained. This leads to increased C3 deposition and C5a release on pro-inflammatory endothelial cells.\",\n      \"method\": \"C3 convertase activity assay, surface plasmon resonance binding assays, complement deposition on endothelial cells, patient cohort analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted convertase assay plus binding kinetics and cell-based functional assays\",\n      \"pmids\": [\"22246034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"C3a promotes survival of astrocytes under ischemic stress by reducing ERK signaling and caspase-3 activation in a C3aR-dependent manner. Chemical ischemia upregulates C3aR expression in astrocytes; C3aR-deficient astrocytes are not protected by C3a.\",\n      \"method\": \"C3aR knockout primary astrocytes, chemical ischemia model, ERK signaling assay, caspase-3 activation assay, cell viability assay\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined signaling mechanism and orthogonal viability readouts\",\n      \"pmids\": [\"25972241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"C3a-C3aR signaling stimulates post-ischemic neural plasticity: C3a overexpression increases GAP43 expression (marker of axonal sprouting) and synaptic density after stroke, while C3aR deficiency decreases them. Intranasal C3a treatment accelerates motor function recovery after stroke.\",\n      \"method\": \"GFAP-C3a transgenic mice, C3aR knockout mice, photothrombotic stroke model, GAP43 immunostaining, synaptic density measurement, behavioral testing\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function and KO loss-of-function with defined cellular and behavioral outcomes\",\n      \"pmids\": [\"27956400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Complement C3a-C3aR signaling promotes skeletal muscle regeneration by regulating monocyte/macrophage function and trafficking: C3aR deficiency impairs regeneration and reduces monocyte infiltration. C3aR-deficient monocytes show reduced adhesion molecules, cytokines, and antigen processing genes. Exogenous CCL5 rescues defects in C3aR-deficient mice.\",\n      \"method\": \"C3 and C3aR knockout mice, Cfb knockout (alternative pathway), cardiotoxin injury model, monocyte gene expression analysis, CCL5 reconstitution experiment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic knockouts with defined cellular mechanism and reconstitution experiment\",\n      \"pmids\": [\"29233958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C3a stimulates macrophages via pertussis toxin-sensitive G proteins coupled to the C3a receptor (C3aR), inducing intracellular Ca2+ mobilization and superoxide generation. The C3aR on macrophages has two classes of binding sites (high-affinity Kd ~2.7 nM; low-affinity Kd ~51 nM).\",\n      \"method\": \"125I-C3a binding/Scatchard analysis, intracellular calcium measurement, superoxide assay, pertussis toxin inhibition\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative receptor binding and G protein coupling, single lab\",\n      \"pmids\": [\"8406589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C3a and C3a(desArg) enhance LPS- or IL-1beta-induced IL-6 synthesis in human PBMCs via a G protein-coupled, pertussis toxin-sensitive pathway, and activate NF-kappaB and AP-1; they do not induce IL-6 alone. The effect is independent of PGE2 production.\",\n      \"method\": \"Northern blot, ELISA, NF-kappaB/AP-1 EMSA, pertussis toxin inhibition, indomethacin block\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches establishing G-protein pathway, single lab\",\n      \"pmids\": [\"9886419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C3a acts as a chemoattractant for the macrophage cell line J774 via the C3aR in a receptor-mediated fashion; C3a(desArg) lacks chemotactic activity. RBL-2H3 cells transfected with human C3aR also migrate toward C3a but not C3a(desArg), confirming receptor-specific chemotaxis.\",\n      \"method\": \"Boyden chamber chemotaxis assay, fluorescent C3a binding, RT-PCR for C3aR mRNA, C3aR transfectant migration\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific chemotaxis confirmed with transfectants, single lab\",\n      \"pmids\": [\"9603462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Sez6 family members (Sez6, Sez6L, Sez6L2) inhibit C3b opsonization by both classical and alternative pathways by accelerating the decay of C3 convertases and by functioning as cofactors for Factor I-mediated cleavage of C3b (but not C4b).\",\n      \"method\": \"C3b deposition assay, convertase decay assay, Factor I cofactor assay with recombinant Sez6 proteins\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with defined enzymatic activities and substrate specificity\",\n      \"pmids\": [\"33936031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"C3a promotes versican V1 transcription in tubular cells via AKT/β-catenin pathway activation downstream of C3aR, contributing to interstitial fibrosis in FSGS; C3aR knockout decreases versican expression in Adriamycin-treated mice.\",\n      \"method\": \"C3aR knockout mice, pathway inhibitor experiments, microarray, in vitro C3a treatment of tubular cells\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus in vitro mechanistic pathway, single lab\",\n      \"pmids\": [\"30944246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Properdin stabilizes the alternative pathway C3 convertase, and its release into the airways is required for local C3a generation during allergen-induced airway inflammation. Properdin deficiency reduces BAL C3a levels and airway inflammation; intranasal C3a co-administration with properdin to properdin-deficient mice restores airway inflammation.\",\n      \"method\": \"Properdin-deficient mice, anti-properdin antibody blocking, C3a ELISA, intranasal reconstitution experiment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deficiency with reconstitution and defined pathway placement\",\n      \"pmids\": [\"26116506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"C3a and C3aR signaling mediates podocyte damage in primary membranous nephropathy: C3aR antagonism blocks MN plasma-induced podocyte injury (PLA2R upregulation, reduced synaptopodin/viability/migration), and C3aR blockade attenuates proteinuria and glomerular pathology in Heymann nephritis rats.\",\n      \"method\": \"Human podocyte cell assays, C3aR antagonists (SB290157, JR14a), Heymann nephritis rat model, immunofluorescence, electron microscopy\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological blockade in both human cell and in vivo rat model with defined pathological readouts\",\n      \"pmids\": [\"35777783\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Complement C3 is proteolytically cleaved by C3 convertases (classical or alternative pathway) at its alpha-chain, releasing the anaphylatoxin C3a (a 77-residue peptide with a C-terminal arginine essential for receptor binding) and generating C3b, which undergoes a dramatic >85 Å conformational rearrangement that exposes its thioester for covalent attachment to surfaces and reveals binding sites for factor B, factor H, CRIg, and complement receptors; cell-bound C3b is further inactivated by factor I (with factor H or CR1 as cofactors) to iC3b and then C3c/C3dg, regulating opsonization and convertase assembly. C3a signals through its G protein-coupled receptor C3aR (requiring sulfotyrosine 174 for binding) to activate Gi, Rho, and downstream pathways (NF-κB, STAT3, AKT/β-catenin, ERK) in diverse cell types including mast cells, macrophages, endothelial cells, platelets, T cells, neural cells, and podocytes, mediating inflammation, anaphylaxis, phagocytosis, tissue regeneration (liver, muscle, brain), and immune regulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify papers and extract mechanistic discoveries about complement component C3 (the canonical human protein).\n\n**EXCLUDE classifications:**\n- Papers 49, 64, 77 (plant C3/C4 photosynthesis - symbol collision with plant biology)\n- Paper 33, 45 (C3A hepatoma cell line - not about C3 protein)\n- Paper 87 (Clostridium botulinum C3 exoenzyme - different protein)\n- Additional gene2pubmed papers 1, 2, 3, 4, 5, 6, 7, 8, 13, 14, 24, 25, 27 (GWAS/proteomics not mechanistic about C3), 28 (ASP/obesity correlations), 30 (ghrelin study), 16 (AMPs review not C3-specific)\n\nAll other papers describe the canonical complement C3 protein and are KEEP.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1969,\n      \"finding\": \"C3a anaphylatoxin fragment (~7,000 Da, basic peptide) was isolated from C3 and shown to have smooth muscle contracting activity, anaphylatoxin activity, and chemotactic activity; trypsin treatment abolished anaphylatoxin but not chemotactic activity. A serum anaphylatoxin inactivator was identified that destroys C3a activity.\",\n      \"method\": \"Biochemical isolation, smooth muscle bioassay, leukocyte chemotaxis assay, enzymatic inactivation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original isolation with multiple functional assays, foundational paper (475 citations)\",\n      \"pmids\": [\"5778786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"Human C3 consists of alpha (120 kDa) and beta (75 kDa) chains linked by disulfide bonds and noncovalent forces. C3 convertase acts on the alpha-chain, cleaving C3a from its N-terminus and transiently exposing a binding region in C3b for biological membranes. Subsequent cleavage by C3b-inactivator or trypsin releases C3c but not C3d from bound C3b, indicating C3b binds membranes through the C3d portion of the molecule.\",\n      \"method\": \"SDS-PAGE, biochemical characterization, enzymatic cleavage studies, receptor binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biochemical methods establishing chain structure and fragment binding sites, highly cited foundational paper\",\n      \"pmids\": [\"1056006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"Human C3a anaphylatoxin is a 77-amino-acid single polypeptide chain with a primary structure containing three disulfide linkages forming a disulfide knot, with functionally important residues concentrated in the 14 C-terminal residues. The COOH-terminal region (Leu-Ala-Arg) is essential for smooth muscle contraction and histamine release from mast cells.\",\n      \"method\": \"Amino acid sequencing from cyanogen bromide cleavage, tryptic/chymotryptic digestion, bioassay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary structure determination with functional validation of C-terminal requirement\",\n      \"pmids\": [\"1238393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"C3a anaphylatoxin purified from both classical (C4,2 enzyme) and alternative pathway activation is identical; the C-terminal arginine (Leu-Ala-Arg) is essential for smooth muscle contraction and histamine release from mast cells in both human and porcine C3a.\",\n      \"method\": \"Purification from complement-activated serum, bioassays (smooth muscle contraction, vascular permeability, histamine release), amino acid composition, N-terminal sequencing\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification with functional characterization and C-terminal modification experiments\",\n      \"pmids\": [\"803505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1977,\n      \"finding\": \"C3b and C3d fragments of C3 function as distinct opsonins recognized by separate receptors on monocytes and PMN. Monocytes bind both C3b and C3d and respond to both as opsonins. PMN lack C3d receptors and respond only to C3b. C3 primarily mediates particle binding via complement receptors but does not by itself trigger ingestion; marked synergy exists between C3 and IgG in phagocytosis.\",\n      \"method\": \"Phagocytosis assays with monocyte and PMN monolayers, receptor blocking experiments, opsonization studies\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic cell biology with defined receptor blocking, highly cited (535 citations)\",\n      \"pmids\": [\"833545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1977,\n      \"finding\": \"Human monocytes synthesize C3 in vitro for up to 5 weeks, with C3 produced having the correct allotype, molecular weight, subunit structure, and hemolytic activity. Monocytes from C3-deficient patients synthesize C3 at ~25% of normal rate, indicating C3 synthesis capacity is preserved but reduced.\",\n      \"method\": \"14C amino acid incorporation, allotype analysis, electrophoresis, cycloheximide inhibition, SDS-PAGE\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biosynthesis demonstration with multiple validation methods\",\n      \"pmids\": [\"332718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1978,\n      \"finding\": \"C3a has chemotactic activity for leukocytes, with C3a-des-Arg retaining chemotactic but not anaphylatoxin activity, demonstrating separable functional domains.\",\n      \"method\": \"In vitro chemotaxis assay, leukocyte migration\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay, highly cited (640 citations), C-terminal arginine removal separates activities\",\n      \"pmids\": [\"342601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1979,\n      \"finding\": \"C3b inactivator (C3bINA) and beta-1H act on cell-bound C3b by cleaving the alpha-chain into 60 kDa (C3b alpha-60) and 40 kDa (C3b alpha-40) fragments. The three polypeptides remain linked by disulfide bonds as C3b', which retains C3d antigenicity but loses ability to mediate immune adherence to human erythrocytes and loses ability to form alternative pathway amplification C3-convertase on the cell surface.\",\n      \"method\": \"SDS-PAGE, functional adherence assays, antibody agglutination with anti-C3c and anti-C3d\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical characterization of cleavage products with functional consequence measurement\",\n      \"pmids\": [\"448074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1980,\n      \"finding\": \"C3b inactivator (C3bINA) is a proteinase that, in conjunction with beta-1H or C4b-binding protein, cleaves C3b and C4b respectively. beta-1H is essential as a cofactor for C3bINA to cleave both soluble and cell-surface-bound C3b. The pH optimum is 6.0. Native C3 is not cleaved, but hemolytically inactive (spontaneously inactivated) C3 is cleaved giving alpha-chain fragments of 75 kDa and 43 kDa.\",\n      \"method\": \"Biochemical purification, hemolysis assay, SDS-PAGE fragment analysis, pH optimum determination\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification and in vitro enzymatic characterization with cofactor requirements\",\n      \"pmids\": [\"6451220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Spontaneous hydrolysis of a thioester bond in native C3 generates a C3b-like derivative capable of forming a fluid-phase C3 convertase with factors B, D, and P, and susceptible to factor I cleavage in the presence of factor H. This establishes the mechanism for initial C3 convertase formation in the alternative pathway without prior activation.\",\n      \"method\": \"Nucleophilic reagent (methylamine) treatment, hemolysis assay, sulfhydryl group detection, organomercurial agarose chromatography, factor I/H cleavage assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted biochemical mechanism with multiple orthogonal methods, highly cited (381 citations)\",\n      \"pmids\": [\"6912277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Nucleophilic modification of C3 (by methylamine or freeze-thaw) induces conformational changes similar to C3b, including exposure of a free sulfhydryl group and increased surface hydrophobicity (ANS binding). The rate-limiting step after nucleophilic addition is the conformational rearrangement itself. Fully transconformed nucleophile-modified C3 binds factor B and is susceptible to cleavage by C3b inactivator with its cofactor beta-1H, though at a slower rate than C3b.\",\n      \"method\": \"Circular dichroism (near-UV), ANS fluorescence, kinetic analysis, hemolytic activity assays, factor B binding\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple spectroscopic and functional methods establishing conformational mechanism\",\n      \"pmids\": [\"7284336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"C3b receptors on human PMN are non-randomly distributed in small clusters on the plasma membrane. Multivalent (but not monovalent) ligand cross-linking of C3b receptors triggers rapid endocytosis via a macropinocytotic mechanism within 10 minutes at 37°C. Cell-surface C3b-opsonized complexes require cross-linking (with antibody) for internalization.\",\n      \"method\": \"Indirect immunofluorescence, radiolabeled antibody binding and endocytosis quantitation, pronase accessibility assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and endocytosis experiments with functional consequence\",\n      \"pmids\": [\"7252422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Fluid-phase C3b dimer binds the C3b receptor (CR1) on human erythrocytes with >25-fold higher affinity than monomer (Kd ~9.53 nM). The interaction is specific, saturable, reversible, and non-cooperative, reaching steady state within 10-15 min at 0°C. Receptor density: ~360/erythrocyte, ~20,000/PMN, ~30,000/monocyte, ~21,000/B-lymphocyte.\",\n      \"method\": \"Radiolabeled C3b binding, Scatchard analysis, column chromatography separation of dimer/monomer\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative binding kinetics with multiple cell types\",\n      \"pmids\": [\"7276561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1982,\n      \"finding\": \"Biotinylated C3 retains >90% hemolytic activity and, when bound to erythrocytes, maintains ability to adhere to human C3b receptors. C3 is fragmented normally into C3c and C3d in human serum, with biotin present in both fragments, demonstrating that biotin modification does not disrupt the thioester or receptor-binding sites.\",\n      \"method\": \"NHS-biotin modification, hemolytic assay, avidin-blocking, flow cytometry, electron microscopy with ferritin-avidin\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization with multiple detection methods, single lab\",\n      \"pmids\": [\"7121468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C3a activates human platelets at concentrations of 10⁻¹⁰ to 8×10⁻¹² M, inducing aggregation and serotonin release. C3a-des-Arg (lacking C-terminal arginine) retains equal platelet-stimulating activity and shows equal synergism with ADP, indicating a distinct mechanism from anaphylatoxin activity and suggesting a separate C3a/C3a-des-Arg receptor on platelets. Ultrastructural evidence shows C3a binding to platelet membrane.\",\n      \"method\": \"Gel-filtered platelet aggregation assay, serotonin release assay, ADP synergism, electron microscopy/ultrastructure\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with ultrastructural confirmation, highly cited\",\n      \"pmids\": [\"6604123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Mast cell tryptase generates C3a anaphylatoxin from the C3 alpha-chain in vitro, cleaving it into major fragments. Heparin (also released from mast cell granules) enhances catabolism of C3a by tryptase, acting as a feedback regulator to downregulate C3a activity generated at sites of mast cell activation.\",\n      \"method\": \"SDS-PAGE under reducing/non-reducing conditions, C3a radioimmunoassay, guinea pig ileum bioassay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with multiple detection methods identifying a physiological C3 convertase and regulatory mechanism\",\n      \"pmids\": [\"6339618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"The C3b receptor (CR1) on human erythrocytes acts as a cofactor for cleavage of C3b by the serine proteinase C3b/C4b inactivator (factor I). The cofactor activity of CR1 on tonsil B-lymphocytes is similar but distinct from serum cofactor proteins (factor H, C4bp) in antigenicity, pH-dependence, and substrate specificity. B-lymphocytes contain a large internal pool of CR1 (>80% of total), while essentially all erythrocyte CR1 is surface-exposed.\",\n      \"method\": \"Enzymatic cofactor assay, detergent cell permeabilization, antigenicity comparison, ionic strength dependence\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional assay with mechanistic dissection and cell fractionation\",\n      \"pmids\": [\"6222733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"CR1 (C3b receptor) on human erythrocytes exists in two allotypic forms (F: Mr ~250,000 and S: Mr ~260,000) regulated by two codominant autosomal alleles (distinct from alleles controlling CR1 copy number). Both allotypic forms are functional in binding dimeric C3b with similar affinities (3-5 × 10⁷ M⁻¹). Removal of N-linked oligosaccharides decreases but does not abolish the electrophoretic mobility difference.\",\n      \"method\": \"Polyacrylamide gel electrophoresis, 125I-autoradiography, endoglycosidase-F treatment, C3b binding assay, family genetic analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structural-functional characterization with family genetic analysis establishing codominant inheritance\",\n      \"pmids\": [\"6223944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Substrate-bound (but not soluble) fibronectin and serum amyloid P component activate C3b and C3bi receptor-mediated phagocytosis in cultured human monocytes (not granulocytes). Stimulation of basal membrane surface by substrate-bound fibronectin activates C3 receptors on the apical surface, indicating transmembrane signaling from basal to apical membrane domains. This activation is developmentally regulated in monocytes.\",\n      \"method\": \"Phagocytosis assays, substrate-bound vs. soluble ligand comparison, PMA activation comparison\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of receptor activation with transmembrane signaling demonstration\",\n      \"pmids\": [\"6225825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"CR1 internalization in neutrophils occurs through a macropinocytotic process (not via coated pits), requires receptor cross-linking and intact microfilaments, and results in association with large flattened vacuolar stacks. fMLP stimulates CR1 internalization via a pertussis toxin-sensitive, calcium-independent mechanism, possibly through protein kinase C, without affecting the lack of coated pit association.\",\n      \"method\": \"Electron microscopic immunogold and autoradiography, pertussis toxin inhibition, calcium chelation, phorbol ester stimulation, cytochalasin treatment\",\n      \"journal\": \"Cell regulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — electron microscopy with multiple pharmacological dissections establishing internalization mechanism\",\n      \"pmids\": [\"1826092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Both CR3 (C3bi receptor) and CR1 (C3b receptor) expression on human PMN increases rapidly upon cell activation. The increase involves translocation from an intracellular storage pool (not new protein synthesis), as it occurs within minutes and is not blocked by protein synthesis inhibitors (puromycin, cycloheximide).\",\n      \"method\": \"Monoclonal antibody staining, flow cytometry, protein synthesis inhibitor treatment, stimulation with fMLP\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental demonstration of intracellular pool translocation mechanism\",\n      \"pmids\": [\"6209300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"C3b and iC3b deposit on particulate complement activators with time-dependent kinetics. On classical pathway activators (EIgM, EIgG), C3b is fully converted to iC3b within 15 min. On bacteria (5 species), only 16-28% of bound C3 is converted to iC3b even after 2h, with no conversion to C3d,g or C3d, suggesting the predominant opsonin form encountered by phagocytes on bacteria is C3b, not iC3b.\",\n      \"method\": \"Monoclonal antibody-based radioimmunoassay, SDS-PAGE autoradiography of particle-bound 125I-C3 fragments, Mg-EGTA-defined pathway specificity\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative characterization with multiple activators and isoform-specific antibodies\",\n      \"pmids\": [\"2409200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Human C3 cDNA encodes a 1641-residue precursor consisting of signal peptide (22 aa), beta chain (645 aa), and alpha chain (992 aa) joined by four arginine residues absent in mature protein. Functionally important sites localized include: thioester site, C3a cleavage site, two factor I cleavage sites, and at least two N-linked glycosylation sites. Human C3 shares 77% amino acid identity with mouse C3 and significant homology with alpha-2-macroglobulin and C4.\",\n      \"method\": \"cDNA sequencing, protein sequence comparison, structural prediction\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete cDNA sequence with functional site localization, foundational paper (411 citations)\",\n      \"pmids\": [\"2579379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The alternative pathway complement C3 convertase (C3b,Bb) is a 10.7S complex containing one metal ion (Ni²⁺ or Mg²⁺) in a 1:1 molar ratio per C3b,Bb complex, located in the Bb subunit. The metal ion is not susceptible to chelation by EDTA when in the active complex. Mg²⁺ and Ni²⁺ likely bind to the same site in the enzyme.\",\n      \"method\": \"Sucrose density gradient ultracentrifugation, ⁶³Ni²⁺ radiolabeling, EDTA stability assay, enzymatic activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct demonstration of active complex with metal stoichiometry by radiolabeling\",\n      \"pmids\": [\"6553050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The Ba fragment of factor B (released during C3 convertase formation) specifically binds C3b independently of Bb (demonstrated by cross-linking). Factor B attachment to C3b involves two discrete points of contact: one in the Ba domain and one in the Bb domain, explaining the unidirectionality of alternative pathway C3 convertase decay.\",\n      \"method\": \"DSP cross-linking, 125I-labeled fragment binding, kinetic analysis of Bb dissociation (first-order kinetics, t1/2=2.4 min), hemolytic decay rate measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with cross-linking and kinetic characterization establishing two-site model\",\n      \"pmids\": [\"3643213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"CR1 (C3b/C4b receptor) contains at least 30 short consensus repeats (SCRs) of 60-70 aa organized into at least four long homologous repeats (LHRs) of 450 aa each, connected to a single transmembrane domain. The linear arrangement of ~30 SCRs would extend ~1,140 Å from the plasma membrane, facilitating access to C3b/C4b in immune complexes and cell walls.\",\n      \"method\": \"cDNA cloning and sequencing from tonsillar library, tryptic peptide analysis, structural prediction\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cDNA sequencing revealing protein architecture, highly cited foundational structural paper\",\n      \"pmids\": [\"2951479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Plasma from mammals, reptiles, amphibia, and fishes can cleave human C3b generating identical fragments (alpha-68, alpha-46, alpha-43, alpha-30 from alpha' chain), while cell-bound C3b is degraded to C3c and C3dg. Birds have very limited C3b-cleaving activity and sera from chondrichthyes and agnatha fail to participate. Fish C3b-cleaving activity uniquely requires Ca²⁺ ions.\",\n      \"method\": \"In vitro C3b/C4b cleavage assay with diverse species sera, SDS-PAGE fragment analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative biochemistry establishing evolutionary conservation of C3b degradation pathway\",\n      \"pmids\": [\"3295051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"C3 occupies a central position in complement; review confirms that C3b associates with factors B, H, I, properdin, DAF, MCP, CR1, CR2, CR3 and coordinates the activation, amplification and regulation of the complement response through three pathways (classical, alternative, lectin).\",\n      \"method\": \"Review synthesizing biochemical and molecular studies\",\n      \"journal\": \"Annual review of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — authoritative review consolidating mechanistic findings, no new primary data\",\n      \"pmids\": [\"3052276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"C3a activates mast cells via G protein (Gi subtype) activation, stimulating inositol polyphosphate generation and histamine release. C3a can directly stimulate purified G proteins (measured by GTPase activity), and its potency correlates with G protein stimulation capacity. C3a may activate mast cells either via direct G protein activation or through a cationic binding site coupled to the G protein cascade, rather than exclusively via a specific receptor.\",\n      \"method\": \"Histamine release assay, pertussis toxin inhibition, inositol polyphosphate measurement, purified G protein GTPase assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — purified G protein direct stimulation assay plus cellular functional assays\",\n      \"pmids\": [\"1373170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Human PMN synthesize and secrete functional C3 in response to LPS and TNF-alpha (but not unstimulated or IFN-gamma/IL-1 stimulated). C3 produced by PMN contains an intact thioester bond (as assessed by methylamine incorporation and autolytic cleavage), demonstrating that PMN-derived C3 is functional.\",\n      \"method\": \"Northern blot for C3 mRNA, ELISA, immunoprecipitation, [35S]methionine labeling, [14C]methylamine incorporation\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biosynthesis with functional thioester characterization\",\n      \"pmids\": [\"1500721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Guinea pig macrophages express two classes of C3a receptor (high-affinity: Kd=2.7 nM, ~63,000 sites/cell; lower-affinity: Kd=51 nM, ~120,000 sites/cell). C3a triggers transient intracellular Ca²⁺ mobilization with homologous desensitization, and superoxide generation. Both responses are blocked by pertussis toxin (Gi coupling). Superoxide generation is inhibited by staurosporine but more resistant than PMA-induced response, suggesting involvement of a protein kinase distinct from PKC.\",\n      \"method\": \"¹²⁵I-C3a Scatchard binding analysis, Ca²⁺ fluorescence, superoxide assay, pertussis toxin and staurosporine inhibition\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative receptor binding kinetics with multiple signaling pathway dissections\",\n      \"pmids\": [\"8406589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C3a and C5a release histamine from human skin mast cells in a concentration-dependent, rapid manner (complete within 15 seconds), requiring the C-terminal arginine for activity. Histamine release is non-cytotoxic, independent of extracellular calcium, and mediated by a site distinct from substance P, acting through different receptor interactions.\",\n      \"method\": \"Histamine assay, PGD2 assay, 2-deoxy-D-glucose/antimycin A metabolic inhibition, calcium removal, substance P antagonist comparison\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple pharmacological tools\",\n      \"pmids\": [\"7513741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Adipose tissue expresses factor D, factor B, and C3, and activates the alternative complement pathway, generating C3a/Acylation Stimulating Protein (C3a/ASP), a stimulator of triglyceride synthesis. Preadipocytes express complement regulatory proteins Crry and factor H, whose expression decreases upon differentiation, potentially permitting complement activation in mature adipocytes.\",\n      \"method\": \"RNA expression analysis, RIA for murine C3a, lean vs. obese mouse comparison, plasma triglyceride correlation\",\n      \"journal\": \"Obesity research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — expression and correlation data with limited mechanistic follow-up on C3a/ASP generation\",\n      \"pmids\": [\"8946437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Extrahepatic C3 contributes measurably to circulating C3: bone marrow-derived (monocyte) C3 contributes 0.1-2.6% during inflammatory stimulation post-BMT; total extrahepatic C3 (liver transplant data) contributes 3.1-5.7% in steady state. Monocytes are the myeloid source of extrahepatic C3, with negligible resting-state contribution but significant potential during inflammation.\",\n      \"method\": \"ELISA and immunoblotting with allotype-specific mAb in BMT and liver transplant recipients, cell culture with immunostaining\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural allotypic mismatch experiment quantifying in vivo extrahepatic contribution\",\n      \"pmids\": [\"8609428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human astrocyte cell lines express a specific, functional C3a receptor (C3aR) identical in sequence to the leukocytic C3aR. High-affinity binding sites (Kd=1-2 nM, 20,000-80,000 sites/cell) mediate C3a-induced transient intracellular Ca²⁺ elevation. The C-terminal arginine of C3a is required for full Ca²⁺ response.\",\n      \"method\": \"¹²⁵I-C3a binding assay, Scatchard analysis, RT-PCR with three primer sets, Western blot with anti-C3aR, Ca²⁺ fluorescence, flow cytometry\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods confirming receptor expression and function on astrocytes\",\n      \"pmids\": [\"9832147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"C3a and C3a-des-Arg enhance LPS- and IL-1beta-induced IL-6 production in human PBMCs via a pertussis toxin-sensitive G protein-coupled pathway, and enhance NF-kappaB and AP-1 binding activity. Neither C3a nor C3a-des-Arg alone induce IL-6, but both enhance LPS-induced IL-6 mRNA levels.\",\n      \"method\": \"Northern blot, ELISA, pertussis toxin inhibition, EMSA (NF-kappaB and AP-1 binding), indomethacin control\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing G protein-dependent NF-kappaB/AP-1 pathway\",\n      \"pmids\": [\"9607842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"C3a receptor (C3aR) is constitutively expressed at high levels in cortical and hippocampal neurons and Purkinje cells of the normal CNS, as well as in primary astrocytes and microglia. In experimental allergic encephalomyelitis (EAE), C3aR expression increases on microglia and infiltrating monocyte-macrophages, while neuronal expression remains unchanged.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, RT-PCR, EAE model\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization study in multiple CNS cell types, single lab\",\n      \"pmids\": [\"10340761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"C3a and C3a(desArg) enhance LPS-induced IL-6 synthesis by adherent PBMCs but suppress IL-6 in non-adherent PBMCs, demonstrating cell-type-specific, bidirectional immunomodulatory effects. The mechanism involves NF-kappaB and AP-1 activation via a pertussis toxin-sensitive G protein pathway.\",\n      \"method\": \"ELISA, Northern blot, pertussis toxin inhibition, EMSA\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — demonstration of opposing effects in adherent vs non-adherent cells via Gi pathway\",\n      \"pmids\": [\"9886419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Genetic deletion of the C3a receptor (C3aR) in mice protects against allergen-induced changes in lung physiology in an allergic airway disease model. Human asthmatics generate significant C3a following intrapulmonary allergen deposition but not saline, establishing that C3a-C3aR signaling participates in allergen-induced airway responses.\",\n      \"method\": \"C3aR knockout mouse model, pulmonary physiology measurements, bronchoalveolar lavage C3a measurement in human subjects\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined physiological phenotype and human data\",\n      \"pmids\": [\"10984054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C3 deficiency in ldlr(-/-) mice leads to larger atherosclerotic lesions with greater macrophage content, less smooth muscle cell content, and less collagen, indicating C3-dependent complement activation promotes maturation of atherosclerotic lesions beyond the foam cell stage.\",\n      \"method\": \"ldlr/C3 double-knockout mouse model, en face lesion analysis, immunohistochemistry for macrophages, SMCs, collagen\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with defined histological phenotype\",\n      \"pmids\": [\"12081998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pro-carboxypeptidase R (TAFI/proCPB) removes C-terminal arginine from C3a more efficiently than carboxypeptidase N (CPN), inactivating C3a anaphylatoxin activity. TAFI is upregulated in inflammation, suggesting it is a major physiological inactivator of C3a.\",\n      \"method\": \"Enzymatic inactivation assay with C3a and C5a octapeptides, comparison with CPN activity\",\n      \"journal\": \"Microbiology and immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay comparing two carboxypeptidases\",\n      \"pmids\": [\"11939578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C3a receptor (C3aR) in endothelial cells couples to G-alpha-12/13 (not Gi) causing transient actin stress fiber formation via Rho activation; this is not pertussis toxin-sensitive. In contrast, C5aR on endothelial cells couples to Gi (pertussis toxin-sensitive), causing delayed sustained cytoskeletal retraction, paracellular permeability increase, and eosinophil transmigration facilitation. C5a, but not C3a, is chemotactic for endothelial cells.\",\n      \"method\": \"Actin staining, pertussis toxin inhibition, Rho activation assay, transendothelial resistance measurement, chemotaxis assay, immune precipitation/EGFR phosphorylation\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling assays with pharmacological dissection distinguishing C3aR from C5aR coupling\",\n      \"pmids\": [\"12165538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C3 and C5 complement components are essential for liver regeneration after partial hepatectomy. C3a and C5a mediate their effect by interacting with IL-6/TNF-alpha signaling and activating NF-kappaB/STAT-3 in the early priming stages of hepatocyte proliferation. Dual C3/C5 deficiency is more severe than either alone, reversed by combined C3a/C5a reconstitution.\",\n      \"method\": \"C3-/- and C5-/- mouse models, partial hepatectomy, liver histology, mortality assessment, cytokine measurement, NF-kappaB/STAT-3 activation assays, C3a/C5a reconstitution\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with reconstitution and defined signaling pathway, highly cited\",\n      \"pmids\": [\"12975457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tyrosine 174 in the second extracellular loop of C3aR is posttranslationally modified by sulfation, and this sulfotyrosine is essential for binding of native C3a. Mutation of Tyr174 to Phe completely blocks C3a binding but allows signaling by synthetic C3a agonist peptides, consistent with a two-site model of ligand association where sulfoTyr174 is the primary C3a docking site.\",\n      \"method\": \"Site-directed mutagenesis of five C3aR extracellular loop tyrosines to Phe, competitive binding with ¹²⁵I-C3a, calcium mobilization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional binding and signaling assays, identifies specific PTM essential for ligand binding\",\n      \"pmids\": [\"12871936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"C3a-C3aR signaling inhibits the ability of antigen-presenting cells (APCs) to drive Th2 cell differentiation. C3a inhibits splenocyte (but not purified T cell) Th2 cytokine secretion by inducing IL-12 secretion from APCs. C3aR(-/-) mice show exaggerated Th2 response to epicutaneous OVA sensitization via elevated IgG1 and Th2 cytokines.\",\n      \"method\": \"C3aR knockout mice, OVA epicutaneous sensitization model, cytokine ELISA (IL-4, IL-5, IL-10, IL-12), APC/T cell separation experiments, OVA-TCR transgenic T cell assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with cell separation experiments identifying IL-12 as the APC-derived mediator\",\n      \"pmids\": [\"15286806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The complement system regulates adaptive immunity through C3a and C5a acting on dendritic cells (DCs) and T cells. DCs and T cells locally produce complement components and express C3aR/C5aR. Absence of C3aR signaling impairs DC capacity to drive Th1 responses and favors Treg emergence.\",\n      \"method\": \"Review synthesizing studies on complement receptor expression and function in adaptive immunity\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review; included because it synthesizes primary mechanistic data on C3/DC/T cell interactions\",\n      \"pmids\": [\"15454921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structures of native C3 and C3c reveal 13 domains (9 previously unpredicted) including the macroglobulin (MG) domain ring and a thioester-containing domain (TED). A double mechanism prevents spontaneous thioester hydrolysis. Marked conformational changes in the alpha-chain, including movement of a critical interaction site through the beta-chain ring, establish a conformation-dependent mechanism for C3 activation, regulation, and function.\",\n      \"method\": \"X-ray crystallography of native C3 and C3c at high resolution\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional interpretation, highly cited (439 citations)\",\n      \"pmids\": [\"16177781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Complement C3a enhances CXCL12 (SDF-1)-induced chemotaxis of hematopoietic progenitors and B-lineage cells independently of the classical C3aR. C3a-desArg (which does not bind C3aR) and C4a also potentiate CXCL12 chemotaxis, and C3aR-knockout BM cells respond normally. C3a directly increases CXCL12 binding affinity on CXCR4+/C3aR- cells, suggesting a direct C3a-CXCL12 protein interaction.\",\n      \"method\": \"Chemotaxis assay (Boyden chamber), C3aR inhibitor SB290157, C3aR knockout mice, flow cytometry, competitive binding assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple approaches excluding C3aR, but direct protein-protein interaction proposed without direct biochemical confirmation\",\n      \"pmids\": [\"16148115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of C3b at 4-Å resolution reveals that proteolytic activation causes dramatic conformational rearrangements of 12 domains. The thioester-containing domain (TED) moves >85 Å from its buried position in native C3, becoming fully exposed for covalent attachment to target surfaces. These domain rearrangements expose previously hidden binding sites for factor B, factor H, and complement regulators.\",\n      \"method\": \"X-ray crystallography at 4-Å resolution\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure revealing mechanism of thioester exposure and binding site rearrangement (295 citations)\",\n      \"pmids\": [\"17051160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of C3b in complex with CRIg reveals that C3 activation induces >80 Å movement of the thioester domain. CRIg inhibits alternative pathway convertases: structure-function studies with CRIg mutants show CRIg acts as an inhibitor of C3b,Bb convertase formation. CRIg therefore functions both as a phagocytic receptor (binding C3b and iC3b) and as a complement inhibitor.\",\n      \"method\": \"X-ray crystallography of C3b-CRIg complex, CRIg mutant structure-function analysis, convertase inhibition assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and functional validation (192 citations)\",\n      \"pmids\": [\"17051150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CRIg, a complement receptor of the immunoglobulin superfamily expressed on Kupffer cells, binds C3b and iC3b and is required for efficient phagocytosis of complement C3-opsonized particles. CRIg-deficient mice are unable to efficiently clear C3-opsonized pathogens from circulation, resulting in increased infection and mortality.\",\n      \"method\": \"CRIg knockout mouse model, in vivo clearance assay, phagocytosis assay with Kupffer cells, binding studies\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with in vivo clearance phenotype, highly cited (454 citations)\",\n      \"pmids\": [\"16530040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3b structure reveals marked loss of secondary structure in the CUB domain and translocation of the thioester domain, providing molecular basis for conformational changes in C3→C3b conversion. A covalently bound N-acetyl-L-threonine residue in the structure demonstrates the geometry of C3b attachment to surface hydroxyl groups.\",\n      \"method\": \"X-ray crystallography of C3b\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with covalent adduct demonstrating attachment mechanism\",\n      \"pmids\": [\"17051152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3a and C5a bioactive fragments are present in AMD patient drusen and induce VEGF expression in vitro and in vivo. Genetic ablation or pharmacological blockade of C3a or C5a receptors reduces VEGF expression, leukocyte recruitment, and choroidal neovascularization (CNV) after laser injury.\",\n      \"method\": \"Immunohistochemistry of drusen, in vitro VEGF assay, C3aR and C5aR knockout mice, laser-induced CNV model, VEGF measurement, leukocyte quantification, antibody neutralization and receptor antagonism\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation plus pharmacological intervention with defined pathway (534 citations)\",\n      \"pmids\": [\"16452172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3a-derived peptide CNY21 (C3a residues Cys57-Arg77) has direct antifungal activity against Candida, binding cell surfaces and inducing membrane perturbations and release of extracellular material. Arginine residues are critical for antifungal and membrane-disrupting activity. Candida isolates induce complement degradation generating C3a.\",\n      \"method\": \"Fluorescence microscopy, electron microscopy, antifungal MIC assay, arginine mutagenesis of peptides\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct antimicrobial mechanism with imaging and mutagenesis, single lab\",\n      \"pmids\": [\"17169328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3a stimulates human keratinocytes (which express C3aR upregulated by IFN-gamma/IFN-alpha) to produce C3 and CCL2, creating an autocrine amplification loop. Skin mast cell tryptase generates fragments with C3a activity from C3 produced by keratinocytes, linking mast cell activation to epidermal complement amplification.\",\n      \"method\": \"RT-qPCR, flow cytometry, microarray, ELISA, tryptase cleavage assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — microarray plus validation with in vitro tryptase cleavage establishing amplification loop\",\n      \"pmids\": [\"16982879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C5L2 (GPR77), previously considered a non-signaling decoy receptor for C5a, is required to facilitate C5a signaling in neutrophils, macrophages, and fibroblasts, and also optimizes C3a-induced signals. C5L2-deficient mice phenocopy C3a/C3aR signaling-deficient mice (hypersensitivity to LPS, reduced OVA-induced airway responsiveness, delayed hematopoietic regeneration).\",\n      \"method\": \"Gene targeting/knockout, in vitro signaling in neutrophils/macrophages/fibroblasts, LPS septic shock model, OVA airway model, gamma-irradiation hematopoietic recovery\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with multiple in vivo and in vitro models, highly cited\",\n      \"pmids\": [\"17322907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The common C3 polymorphism C3F (rs2230199, Arg80Gly) is strongly associated with age-related macular degeneration risk (OR 1.7 for S/F heterozygotes, 2.6 for F/F vs S/S homozygotes), with estimated 22% population attributable risk, establishing C3 as functionally important in AMD pathogenesis.\",\n      \"method\": \"Case-control association study with functional variant in two independent cohorts\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic association with functional variant, mechanistic implication but no direct mechanism experiment\",\n      \"pmids\": [\"17634448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C3b and C4b covalently attach to gonococcal/meningococcal surface proteins (porin Por1B and opacity protein Opa) via ester linkages (C3b) and amide linkages (C4b). Loops 4 and 5 of Por1B are the preferred C4b binding site. All tested Opa proteins (A-I) bind both C3b and C4b, providing a molecular basis for complement-mediated serum sensitivity.\",\n      \"method\": \"Serum complement deposition on mutant strains, hybrid Por molecule mapping, C4A isoform-specific amide linkage confirmation, bacterial opsonization assays\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — covalent attachment characterization on bacterial targets with structural mapping\",\n      \"pmids\": [\"17984207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Factor H has two distinct C3b-binding sites: CCPs 1-4 (Kd ~10-14 μM) and CCPs 19-20 (Kd ~3.5-4.5 μM), with CCPs 6-8 showing weak C3b affinity. Two glycosaminoglycan-binding sites are located at CCPs 7-8 and 19-20. Several previously reported binding sites (CCPs 8-9, 10-15) do not bind heparin, correcting the functional map of factor H.\",\n      \"method\": \"SPR (surface plasmon resonance) with CM5 and C1 chips, heparin-affinity chromatography, gel-mobility shift assay, structural validation\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — SPR binding measurements with multiple constructs and rigorous controls correcting prior data\",\n      \"pmids\": [\"18684951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"C3a and C5a sensitize cutaneous C-nociceptors to heat (increased proportion of heat-responsive fibers, lowered threshold, increased action potentials) and activate A-nociceptors, contributing to heat and mechanical hyperalgesia in vivo. C5a and C3a elevate intracellular Ca²⁺ and facilitate capsaicin-induced Ca²⁺ responses in DRG neurons, and C5aR mRNA is expressed in DRG.\",\n      \"method\": \"Intraplantar injection model (behavioral hyperalgesia), in vitro skin-nerve preparation (electrophysiology of individual nociceptors), Ca²⁺ imaging in DRG neurons\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiological recordings from individual nociceptors combined with Ca²⁺ imaging\",\n      \"pmids\": [\"20031321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Complement C3a, acting via C3aR, is essential for mutual cell-cell attraction (coattraction) of migrating neural crest cells during collective migration. Loss of C3a or C3aR disrupts cohesive cluster maintenance and coordinated collective movement. Coattraction via C3a-C3aR counterbalances contact inhibition and EMT-driven dispersion to maintain cell collective cohesion.\",\n      \"method\": \"Neural crest cell migration assays (Xenopus, chick), C3a/C3aR loss-of-function (morpholinos, dominant negatives), live imaging, mathematical modeling\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic/molecular loss-of-function with live imaging in two vertebrate models, highly cited\",\n      \"pmids\": [\"22118769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"C3a-C3aR signaling in a model of complement-mediated tubulointerstitial injury drives renal leukocyte infiltration, inflammation, and fibrosis (myelomonocytic cells and T cells along injured tubules; collagen I and III deposition). C5aR deficiency alone is inconsequential in this model, but elimination of C5aR abolishes the protective effect of C3aR deficiency, indicating cooperative roles.\",\n      \"method\": \"Crry-/-C3-/- kidney transplantation into C3aR-/- and/or C5aR-/- hosts, histology, immunohistochemistry, renal function\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complex genetic transplant model separating C3aR from C5aR contributions\",\n      \"pmids\": [\"21677637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Adenovirus-mediated overexpression of C3 in murine retina induces complement activation and deposition of membrane attack complex on endothelial cells and photoreceptor outer segments, causing vascular permeability, endothelial proliferation, RPE atrophy, photoreceptor outer segment loss, reactive gliosis, retinal detachment, and reduced retinal function.\",\n      \"method\": \"Subretinal adenovirus injection, ERG, fluorescein angiography, immunohistochemistry, quantitative RT-PCR\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct overexpression model with multiple outcome measures, single lab\",\n      \"pmids\": [\"21357400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The R139W mutation in complement C3 (found in 14 aHUS patients) creates a hyperactive C3 convertase through increased affinity for factor B and reduced binding to membrane cofactor protein (MCP/CD46), with normal factor H regulation. The mutant C3 causes increased C3 deposition, C5a release, and procoagulant tissue-factor expression on pre-activated glomerular endothelial cells.\",\n      \"method\": \"SPR/binding assays for factor B, MCP, and factor H; C3 convertase activity assay; cell deposition assay on activated GEnCs; genetic haplotype analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct convertase activity measurement, binding affinity assays, and cell-based assays with defined mutation\",\n      \"pmids\": [\"22246034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"C3 deficiency in mice reduces cigarette smoke-induced emphysema. Neutrophil elastase cleaves C3 to release C3a, which in turn increases C3aR expression on lung myeloid dendritic cells via autocrine/paracrine signaling. C3aR-deficient mice partially phenocopy C3-deficient mice in attenuated smoke responses.\",\n      \"method\": \"C3-/- and C3aR-/- mouse models, chronic smoke exposure, neutrophil elastase cleavage assay, mDC quantification by flow cytometry, emphysema scoring\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with mechanistic dissection identifying neutrophil elastase as C3 convertase and autocrine C3a-C3aR loop\",\n      \"pmids\": [\"25465103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Properdin (alternative pathway positive regulator) contributes to allergic airway inflammation by promoting local C3a generation in the airways. Intranasal reconstitution of properdin to P-deficient mice at the challenge phase restores airway inflammation; co-administration with anti-C3a mAb prevents this restoration, establishing that properdin acts through C3a production.\",\n      \"method\": \"Properdin-deficient mouse model, OVA sensitization/challenge, anti-C3a mAb neutralization, BAL cell counting and C3a ELISA, intranasal protein reconstitution\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic ablation with reconstitution and antibody neutralization establishing C3a as the effector molecule\",\n      \"pmids\": [\"26116506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"C3a promotes survival of astrocytes under ischemic stress by reducing ERK signaling and caspase-3 activation via C3aR signaling. Ischemia upregulates C3aR expression in astrocytes. C3a protection is absent in C3aR-deficient astrocytes. Pre-treatment with C3a abrogates the neuroprotective phenotype of astrocytes in post-ischemic recovery.\",\n      \"method\": \"Chemical ischemia/oxygen-glucose deprivation in primary cortical astrocytes, C3aR-/- astrocytes, ERK and caspase-3 Western blot, cell viability assay\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout astrocytes with defined signaling readouts, single lab\",\n      \"pmids\": [\"25972","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"Complement C3 is the central effector of the complement system, functioning as the convergence point for classical, alternative, and lectin pathways through proteolytic cleavage by C3 convertases that release the anaphylatoxin C3a and generate C3b, which undergoes a >85 Å conformational rearrangement exposing its thioester domain for covalent surface attachment and cryptic binding sites for factor B, factor H, CRIg, and complement receptors [PMID:1056006, PMID:17051160, PMID:17051150]. C3b deposited on surfaces is regulated by factor I (with factor H or CR1 as cofactors) through sequential cleavage to iC3b and then C3c/C3dg, controlling opsonization, convertase assembly, and phagocytic clearance [PMID:6451220, PMID:448074, PMID:2409200]. C3a signals through its GPCR C3aR — which requires sulfotyrosine 174 for native ligand binding — coupling to Gi, G-alpha12/13, and Rho to activate NF-κB, STAT3, AKT/β-catenin, and ERK pathways in mast cells, macrophages, endothelial cells, platelets, neural cells, and podocytes, mediating anaphylaxis, inflammation, liver and muscle regeneration, neural plasticity after stroke, and collective neural crest cell migration [PMID:12871936, PMID:12975457, PMID:27956400, PMID:29233958, PMID:22118769, PMID:12165538]. Gain-of-function mutations such as C3 R139W cause atypical hemolytic uremic syndrome by generating a hyperactive C3 convertase with increased factor B affinity and reduced regulation by MCP/CD46 [PMID:22246034].\",\n  \"teleology\": [\n    {\n      \"year\": 1975,\n      \"claim\": \"Establishing C3's basic architecture resolved how a single zymogen generates both a soluble inflammatory mediator and an opsonin: C3 convertase cleaves the alpha-chain to release a 77-residue C3a anaphylatoxin (whose C-terminal arginine is essential for receptor activity) and C3b, which attaches to membranes via its C3d region.\",\n      \"evidence\": \"Biochemical fractionation, SDS-PAGE, hemolytic assays, and complete amino acid sequencing of C3a\",\n      \"pmids\": [\"1056006\", \"1238393\", \"803505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Thioester chemistry not yet identified\", \"Three-dimensional structure unknown\", \"Mechanism of C3b surface attachment unresolved\"]\n    },\n    {\n      \"year\": 1980,\n      \"claim\": \"Defining the factor I/factor H regulatory axis explained how host surfaces are protected from C3b amplification: factor I cleaves C3b only in the presence of cofactor factor H (or CR1), generating iC3b which abolishes convertase activity and immune adherence.\",\n      \"evidence\": \"In vitro protease reconstitution assays with purified factor I, factor H, and cell-bound or soluble C3b substrates\",\n      \"pmids\": [\"6451220\", \"448074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cofactor requirement unknown\", \"Fate of iC3b (further degradation to C3dg/C3c) not yet characterized in this system\"]\n    },\n    {\n      \"year\": 1981,\n      \"claim\": \"Demonstrating that nucleophilic modification of C3 produces C3b-like conformational changes without proteolysis revealed that thioester reactivity drives the conformational switch, linking the internal thioester to functional activation.\",\n      \"evidence\": \"Near-UV CD, ANS fluorescence, factor B binding, and factor I susceptibility of methylamine-treated C3\",\n      \"pmids\": [\"7284336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Thioester structure not directly visualized\", \"Kinetics of conformational change in vivo unknown\"]\n    },\n    {\n      \"year\": 1983,\n      \"claim\": \"A burst of discoveries characterized C3a and C3b receptor biology: C3a activates platelets at picomolar concentrations, triggers mast cell histamine release in a calcium-independent manner requiring C-terminal arginine, and C3b receptor (CR1) mediates adsorptive endocytosis requiring bivalent crosslinking and also serves as a cofactor for factor I.\",\n      \"evidence\": \"Platelet aggregation/serotonin release, mast cell histamine release, CR1 internalization assays, and CR1 cofactor assays on intact vs. permeabilized cells\",\n      \"pmids\": [\"6604123\", \"7513741\", \"7252422\", \"6222733\", \"6225825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C3a receptor not yet cloned\", \"Signaling pathway downstream of C3a undefined\", \"Molecular basis of CR1 cofactor activity unknown\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Structural characterization of CR1 and the alternative pathway convertase established the modular architecture underlying C3b recognition: CR1 contains four long homologous repeats of short consensus repeats, while the C3 convertase (C3b,Bb) requires a single Mg2+ in the Bb subunit and two contact points with C3b.\",\n      \"evidence\": \"cDNA cloning/sequencing of CR1; sucrose gradient ultracentrifugation with 63Ni tracing of C3b,Bb complex\",\n      \"pmids\": [\"2951479\", \"6553050\", \"3643213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of C3b,Bb complex not available\", \"CR1 domain mapping to C3b/C4b binding not yet complete\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Two advances broadened C3 biology beyond liver-derived serum complement: PMNs synthesize and secrete functional thioester-intact C3 upon inflammatory stimulation, and C3a signals through pertussis toxin-sensitive Gi proteins to mobilize inositol phosphates and activate GTPase activity in mast cells.\",\n      \"evidence\": \"Metabolic labeling (35S-methionine, 14C-methylamine) of PMN-derived C3; pertussis toxin inhibition and GTPase assays with purified G proteins\",\n      \"pmids\": [\"1500721\", \"1373170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Local C3 production contribution to tissue defense not quantified in vivo\", \"C3aR molecular identity still unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Quantitative receptor pharmacology showed C3aR on macrophages has two binding affinities (Kd ~2.7 nM and ~51 nM), and C3a/C3a(desArg) synergize with LPS/IL-1β to amplify IL-6 via NF-κB/AP-1, positioning C3a as a co-stimulatory signal rather than a sole inflammatory trigger.\",\n      \"evidence\": \"125I-C3a Scatchard analysis on macrophages; NF-κB/AP-1 EMSA and IL-6 ELISA with pertussis toxin in PBMCs\",\n      \"pmids\": [\"8406589\", \"9886419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for two-affinity binding not resolved\", \"In vivo relevance of co-stimulatory signaling not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Genetic and reconstitution experiments revealed C3a's essential role in liver regeneration (via NF-κB/STAT3/IL-6) and identified sulfotyrosine 174 on C3aR as the critical C3a docking determinant, defining both a physiological non-immune function and the receptor's ligand-binding mechanism.\",\n      \"evidence\": \"C3/C5 KO mice with partial hepatectomy and C3a/C5a reconstitution; Y174F mutagenesis with radioligand binding and calcium assays\",\n      \"pmids\": [\"12975457\", \"12871936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of C3a–C3aR complex unavailable\", \"Downstream effectors in hepatocytes not fully mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Crystal structures of C3b alone and in complex with CRIg provided the first atomic-level understanding of complement activation: the thioester domain moves >85 Å upon C3a release, exposing cryptic sites for factor B and regulators, and CRIg binds C3b/iC3b to inhibit the alternative pathway convertase while promoting phagocytosis.\",\n      \"evidence\": \"X-ray crystallography at 4 Å resolution (C3b) and C3b–CRIg co-crystal with mutagenesis and convertase inhibition assays\",\n      \"pmids\": [\"17051160\", \"17051150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length C3 structure at higher resolution not yet available\", \"Structural basis of factor B binding to C3b not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanding C3a functions beyond immunity, C3a-C3aR signaling was shown to mediate collective neural crest cell migration during vertebrate development, establishing complement as a morphogenetic signal.\",\n      \"evidence\": \"In vivo C3aR knockdown with live imaging of neural crest cluster cohesion\",\n      \"pmids\": [\"22118769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of C3a in embryonic tissue not identified\", \"Whether C3a acts as a chemotactic gradient or contact-dependent signal unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The C3 R139W gain-of-function mutation linked complement to atypical hemolytic uremic syndrome by creating a hyperactive C3 convertase with increased factor B affinity and reduced MCP regulation, causing excessive C3 deposition on endothelial cells.\",\n      \"evidence\": \"Convertase activity assays, SPR binding kinetics, complement deposition on endothelial cells, patient cohort\",\n      \"pmids\": [\"22246034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of how R139W alters factor B and MCP binding unknown\", \"Contribution of other aHUS-associated C3 mutations not systematically compared\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"C3a-C3aR signaling was established as a neural repair pathway: C3a promotes post-stroke neural plasticity by increasing axonal sprouting (GAP43) and synaptic density, while also protecting astrocytes from ischemic death by suppressing ERK/caspase-3 activation.\",\n      \"evidence\": \"GFAP-C3a transgenic and C3aR KO mice in photothrombotic stroke models; C3aR KO astrocytes in chemical ischemia\",\n      \"pmids\": [\"27956400\", \"25972241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous vs. non-cell-autonomous effects in neurons not separated\", \"Optimal therapeutic window for C3a administration undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"C3a-C3aR signaling drives tissue fibrosis in kidney disease through AKT/β-catenin-mediated transcription of versican V1 in tubular cells, and mediates podocyte injury in membranous nephropathy.\",\n      \"evidence\": \"C3aR KO mice in Adriamycin nephropathy; C3aR antagonists in podocyte assays and Heymann nephritis rat model\",\n      \"pmids\": [\"30944246\", \"35777783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of autocrine vs. paracrine C3a in kidney pathology not established\", \"Whether C3aR antagonism has therapeutic benefit in human kidney disease untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Sez6 family proteins were identified as novel complement regulators that inhibit C3b opsonization by accelerating C3 convertase decay and acting as factor I cofactors specific to C3b, expanding the repertoire of neuronal complement regulators.\",\n      \"evidence\": \"In vitro C3b deposition, convertase decay, and factor I cofactor assays with recombinant Sez6/Sez6L/Sez6L2\",\n      \"pmids\": [\"33936031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of Sez6-mediated complement regulation in neurons not demonstrated\", \"Structural basis of Sez6–C3b interaction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of the C3a–C3aR signaling complex, how intracellular (autocrine) C3 processing contributes to T cell and other immune cell functions, and the therapeutic window and safety profile of C3/C3a modulation in regenerative versus pathological contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution C3a–C3aR co-structure available\", \"Intracellular C3 processing pathway not captured in this timeline\", \"Systematic comparison of C3a roles across regenerative vs. pathological tissues lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 6, 9, 17, 22, 29, 31, 32, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 13, 37, 39]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 13, 16, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 7, 10, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 3, 13, 15, 19, 24, 25, 27, 37, 39]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 21, 22, 23, 31, 32, 35, 38, 40]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [6, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [26, 30, 38, 40]}\n    ],\n    \"complexes\": [\n      \"C3 convertase (C3b,Bb)\",\n      \"C3 convertase (C4b2a)\",\n      \"C3b-CRIg complex\"\n    ],\n    \"partners\": [\n      \"CFB\",\n      \"CFH\",\n      \"CFI\",\n      \"CR1\",\n      \"C3AR1\",\n      \"VSIG4\",\n      \"CD46\",\n      \"SEZ6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (refusal — no on-target evidence) ---\n"}